SMU1 and neoplasm: Building on previous studies that targeting highly conserved genes can yield therapeutic effects comparable to targeting driver mutations [72], we propose that SMU1 and other conserved mini-drivers represent promising therapeutic targets, particularly for tumors with high inter-tumor heterogeneity or acquired drug resistance, as they target shared vulnerabilities across diverse tumors.